- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Creative Medical completes enrollment in chronic back pain trial | 3 | Investing.com | ||
| CREATIVE MEDICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| Do | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation ... | 199 | GlobeNewswire (Europe) | All patients enrolled and treated across original and FDA-cleared expansion cohorts Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in... ► Artikel lesen | |
| 07.08. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz, CELZ-101 and CELZ-201 Diabetes Platforms | 380 | GlobeNewswire (Europe) | PHOENIX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 02.07. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.07. | Creative Medical gibt Update zur Geschäftsentwicklung: Fortschritte bei Zelltherapie und Biodefense-Programmen | 2 | Investing.com Deutsch | ||
| 01.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Issues Mid-Year Update | 444 | GlobeNewswire (Europe) | PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 30.06. | Creative Medical secures $4.5M through warrant exercise deal | 1 | Investing.com | ||
| 30.06. | Creative Medical sichert sich 4,5 Mio. US-Dollar durch Vereinbarung zur Optionsschein-Ausübung | 2 | Investing.com Deutsch | ||
| 30.06. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds | 1 | GlobeNewswire (USA) | ||
| 25.06. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 22.06. | FDA genehmigt Studienerweiterung für Rückenschmerztherapie von Creative Medical | 3 | Investing.com Deutsch | ||
| 22.06. | FDA clears Creative Medical trial expansion for back pain therapy | 1 | Investing.com | ||
| 22.06. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain | 339 | GlobeNewswire (Europe) | PHOENIX, June 22, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 16.06. | Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards | 1 | GlobeNewswire (USA) | ||
| 08.05. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.04. | Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies | 1 | GlobeNewswire (USA) | ||
| 24.04. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | - | SEC Filings | ||
| 20.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 13.01. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain | 402 | GlobeNewswire (Europe) | PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,710 | +0,84 % | Dax lässt nach - Qiagen-Papiere gefragt | Frankfurt/Main - Am Donnerstag hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 25.983 Punkten berechnet, ein Minus in Höhe von 0,4 Prozent im Vergleich zum Vortagesschluss. Nach... ► Artikel lesen | |
| MODERNA | 134,26 | +12,73 % | Termin-Börse daily: Unser Moderna-Call explodiert um 420 % - hier ist der Grund | MODERNA schießt heute vorbörslich um rund 100 % nach oben. Auslöser sind positive Phase-III-Daten für den gemeinsam mit MERCK entwickelten mRNA-Krebsimpfstoff gegen Melanome. Nach Angaben des Unternehmens... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,330 | +4,71 % | Summit Therapeutics: Aktie legt nach Hochstufung durch Bernstein zu | ||
| AMYLYX PHARMACEUTICALS | 37,440 | -1,86 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| BIONTECH | 98,55 | +1,76 % | Moderna-Aktie explodiert: Revolutionärer Krebsimpfstoff sorgt für Börsenrallye - BioNTech profitiert | Eine bahnbrechende Krebsstudie katapultiert den Moderna-Kurs an der Nasdaq in neue Höhen und entfacht auch ein Kursfeuerwerk bei BioNTech. Die mRNA-Technologie steht vor einem historischen Durchbruch... ► Artikel lesen | |
| IMMIX BIOPHARMA | 14,950 | +9,85 % | Kehoe Law Firm, P.C.: Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims | Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma")... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,85 | +0,04 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| RECURSION PHARMACEUTICALS | 3,565 | +9,69 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| IMMUNOME | 29,620 | +5,75 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| KYMERA THERAPEUTICS | 127,37 | +5,22 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,170 | +4,30 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 365,80 | -0,61 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 31,440 | +10,98 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| ERASCA | 17,880 | +1,59 % | Erasca, Inc. - 8-K, Current Report | ||
| INHIBRX BIOSCIENCES | 122,00 | +16,26 % | Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target |
Das Unternehmen CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +4,13 % bei einem Aktienkurs von 1,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.